AOD 9604 vs tirzepatide
Tirzepatide is the most effective weight loss drug ever brought to market. AOD 9604 is a specialized lipolytic peptide that didn't meet its Phase IIb endpoint. Here's the honest comparison — and the specific cases where AOD 9604 still has a niche.
- Tirzepatide produces ~21–22% body weight loss at 72 weeks in the SURMOUNT-1 trial — the largest effect ever recorded for an obesity drug.
- AOD 9604 produced ~2.6 kg at 12 weeks in its Phase IIb — an order of magnitude smaller.
- Tirzepatide acts on both GLP-1 and GIP receptors, combining appetite suppression with additional metabolic effects.
- Tirzepatide has a similar GI side effect profile to semaglutide but slightly better tolerability in head-to-head data.
- For raw weight loss, AOD 9604 is not in the same conversation as tirzepatide.
The comparison in one sentence
Tirzepatide and AOD 9604 are both peptides used in the weight loss conversation, but that is where the similarity ends. Tirzepatide is a dual GIP/GLP-1 receptor agonist that produced the largest average weight loss ever recorded in an obesity trial. AOD 9604 is an investigational growth hormone fragment that produced a modest, statistically borderline effect and was not advanced to Phase III. Treating them as substitutes for each other is a category error.
Clinical data side-by-side
| Feature | AOD 9604 | Tirzepatide |
|---|---|---|
| Drug class | hGH fragment 176–191 | Dual GIP / GLP-1 receptor agonist |
| Mechanism | Lipolysis; inhibits lipogenesis | Appetite suppression; improved insulin sensitivity; gastric emptying |
| Pivotal obesity trial | Phase IIb, 12 weeks, n=~500 | SURMOUNT-1, 72 weeks, n=2,539 |
| Average weight loss | ~2.6 kg (12 weeks) | ~21–22% body weight (72 weeks, 15 mg dose) |
| Primary endpoint met? | No | Yes |
| FDA status | Not approved | Approved (Zepbound for obesity, Mounjaro for T2D) |
| Route | Subcutaneous or oral | Subcutaneous weekly |
| Typical dose | 300 mcg daily | 2.5 → 15 mg weekly (titrated) |
| GI side effects | Minimal | Significant (nausea ~25–30%) |
| Muscle loss | None observed | ~25% of weight lost is lean mass |
| Retail cost (cash) | Gray market only | ~$1,060–$1,200/month |
Mechanism differences
Tirzepatide's weight loss comes primarily from appetite suppression (like semaglutide) plus an additional effect through GIP receptor activation. The GIP contribution is not fully characterized but appears to amplify the GLP-1 effect and may provide better glycemic control per unit of weight lost. The net result is an average 15–22% body weight reduction depending on dose, sustained across 72 weeks in SURMOUNT-1.
AOD 9604's mechanism is completely different: it acts peripherally on fat cells to stimulate lipolysis. It does not affect appetite, does not interact with GIP or GLP-1 receptors, and does not slow gastric emptying. This is why the two drugs have such different efficacy profiles — tirzepatide creates a large caloric deficit through appetite, while AOD 9604 only modulates fat metabolism, which has a much smaller downstream effect on body weight.
Where AOD 9604 still has a (narrow) niche
Despite losing the weight loss comparison by a wide margin, AOD 9604 has a few specific characteristics that tirzepatide does not:
- No appetite suppression. For users who explicitly want to maintain or increase food intake — athletes in a specific performance block, for example — appetite suppression is a drawback rather than a feature.
- Preservation of lean mass. Tirzepatide trials report roughly 25% of the weight lost is lean tissue. AOD 9604 protocols have not shown the same lean-mass depletion, consistent with the mechanism.
- No GI side effects. The GI tolerability profile of GLP-1 and GIP/GLP-1 agonists is still their largest practical limitation. AOD 9604 avoids this entirely.
- No effect on gastric emptying. Tirzepatide's delayed gastric emptying can interact with other oral medications. AOD 9604 does not create this interaction.
For most users, tirzepatide wins
If the question is "which drug produces more weight loss," the answer is tirzepatide, and it's not close. The SURMOUNT-1 data is the most robust obesity trial result currently in the literature. AOD 9604 did not pass a similar bar, and the magnitude of its effect is an order of magnitude smaller. For someone whose primary goal is substantial weight loss, AOD 9604 should not be the chosen tool.
For comparison against the other major GLP-1 drug in this space, see the AOD 9604 vs semaglutide page. For a broader look at what AOD 9604 actually does in the body, see the mechanism and benefits page.
Frequently asked questions
Is AOD 9604 as effective as tirzepatide?
No. Tirzepatide produces ~21% body weight loss at 72 weeks in the SURMOUNT-1 trial. AOD 9604 produced ~2.6 kg at 12 weeks — an order of magnitude smaller effect.
Does tirzepatide cause muscle loss?
Yes. Clinical imaging data from tirzepatide trials shows roughly 25% of the weight lost is lean mass. This is one area where AOD 9604 compares favorably, though at much smaller absolute weight loss.
Why would anyone take AOD 9604 over tirzepatide?
Primarily for cases where appetite suppression is undesirable, GI side effects are a dealbreaker, or lean mass preservation is the main concern. These are narrow use cases, but they exist.
Can you combine AOD 9604 with tirzepatide?
No clinical data exists on this combination. The mechanisms do not obviously conflict, but combining unapproved peptides with prescription drugs should only be considered under medical supervision.
Is tirzepatide more expensive than AOD 9604?
Through legitimate channels, yes — tirzepatide retails for ~$1,060–$1,200/month cash. AOD 9604 has no legitimate U.S. prescription pathway, so direct cost comparison is not meaningful.